CompanySTRONasdaqSouth San Francisco, CA

Sutro Biopharma, Inc.

Sutro Biopharma develops single- and dual-payload antibody-drug conjugates using a cell-free platform for cancer treatment.

SEC EDGAR ClinicalTrials.gov sutrobio.com

8-KSep 3Latest SEC filing, period to Aug 31

Sep 8Latest story

September 2026

Sutro Biopharma registers Phase 1 first-in-human trial of ADC STRO-006 in solid tumors

Sep 8Trial updateSTRO-006 Sutro Biopharma, Inc.

August 2026

Sutro Biopharma posts early STRO-004 responses, updates Q2 2026 financials

Aug 12Clinical readoutSTRO-004 Sutro Biopharma, Inc.